The Plasmid DNA Manufacturing Market is estimated to be valued at US$ 901.2 Bn in 2023 and is expected to exhibit a CAGR of 22% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

The Plasmid DNA Manufacturing Market involves production of DNA fragments used in genetic engineering research and pharmaceutical production. Plasmids are circular DNA molecules that can replicate independently of the bacterial chromosome. They are used to introduce new genetic traits into an organism by means of genetic recombination and transformation. Plasmid DNA finds wide applications in gene therapy, genetic research, protein production and genetic engineering. Growing usage of plasmid DNA for vaccine production and increasing demand for cell and gene therapies are major factors driving growth of the market.

Market Overview:
Plasmid DNA manufacturing market involves production and purification of plasmid DNA on large scale for use in biopharmaceutical manufacturing. Plasmid DNA acts as a vector to deliver therapeutic genes into target cells with an aim to prevent or treat diseases. Demand is growing for plasmid DNA from biotechnology and pharmaceutical companies engaged in vaccine development and production of biologics including monoclonal antibodies. Advancements in plasmid engineering techniques have enabled production of high quality and high-yield plasmid DNA to meet the requirements of commercialization and clinical translation.

Market key trends:
Plasmid DNA manufacturing market is witnessing high growth owing to rising demand for cell and gene therapies. Plasmid DNA is widely used as a therapeutic agent and/or vector for gene delivery in various cell and gene therapy applications including cancer immunotherapy. Growing pipeline of cell and gene therapy products and increasing approvals for commercially marketed therapies are spurring demand for high quality plasmid DNA. Technological advancements in plasmid engineering, development of high-yield producer cell lines and automated upstream and downstream manufacturing processes are also fueling plasmid DNA production scale-up. Large biopharmaceutical players are actively investing and partnering with contract development and manufacturing organizations to enhance plasmid DNA manufacturing capabilities and cater to the evolving demand.

Porter's Analysis

Threat of new entrants: The Plasmid DNA Manufacturing market requires high initial investments and strict regulatory processes which act as a deterrent for new entrants.

Bargaining power of buyers: The presence of multiple plasmid DNA manufacturers gives buyers/customers bargaining power to negotiate on price and demand customized services.

Bargaining power of suppliers: Suppliers of raw materials like growth media and reagents have some bargaining power due to specialized skills required for production.

Threat of new substitutes: There exists no close substitute for plasmid DNA used in various biopharma applications currently.

Competitive rivalry: The Plasmid DNA Manufacturing market is highly competitive with presence of major global players.

SWOT Analysis

Strength: The Plasmid DNA Manufacturing market is growing rapidly owing to increasing adoption of plasmid DNA in cell and gene therapies, vaccines.

Weakness: Manufacturing of plasmid DNA is a complex and compliance-intensive process requiring extensive validation and quality control activities. High production costs also acts as a limitation.

Opportunity: Increasing R&D investment in cell and gene therapies present significant growth opportunities. Untapped emerging markets also offer scope for expansion.

Threats: Stringent regulations and disruptions due to unforeseen circumstances like the Covid-19 pandemic pose challenges.

Key Takeaways

The global Plasmid DNA Manufacturing market is expected to witness high growth at a CAGR of 22% over the forecast period, due to increasing demand for plasmid DNA in cell and gene therapy development and manufacturing. North America currently dominates the market owing to presence of major players and robust biopharmaceutical industry in the region.

Regional analysis Europe is also among the fasted growing regions in the Plasmid DNA Manufacturing market supported by increasing funding for cell and gene therapy research.

Key players operating in the Plasmid DNA Manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga.

Read More:

https://www.ukwebwire.com/plasmid-dna-manufacturing-market-opportunity-analysis-2023-2030/